申请人:American Home Products Corporation
公开号:US06046239A1
公开(公告)日:2000-04-04
Compounds of the formula: ##STR1## wherein: R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7 and R.sub.8 are, independently, hydrogen, COOR.sub.15, halogen, nitro, cyano, C.sub.1-10 alkoxy, C.sub.1-10 haloalkoxy, sulfonic acid, C.sub.1-10 alkylsulfonyl, C.sub.6-12 arylsulfonyl, C.sub.6-12 aralkylsulfonyl, C.sub.1-10 alkylsulfinyl, C.sub.6-12 alkylsulfinyl, C.sub.6-12 aralkylsulfinyl, sulfamoyl, C.sub.1-10 alkylsulfamido, C.sub.6-12 alkylsulfamido, C.sub.1-10 alkanoyl, C.sub.6-12 aryloyl, C.sub.6-12 aralkanoyl, amino, C.sub.1-10 alkylamino, C.sub.2-10 dialkylamino, C.sub.6-12 aralkylamino, C.sub.6-12 arylamino, carboxamido, C.sub.1-10 alkylcarboxamido, C.sub.6-12 arylcarboxamido, C.sub.1-10 haloalkyl, C.sub.1-10 alkyl, C.sub.2-12 alkenyl, C.sub.6-12 aryl, C.sub.6-12 aralkyl; with the proviso that at least one of R.sub.4 and R.sub.5 is COOR.sub.15 ; R.sub.9 is hydrogen, C.sub.1-10 alkyl and C.sub.1-10 haloalkyl; R.sub.10 is hydrogen, C.sub.1-10 alkyl, C.sub.1-10 haloalkyl, or C.sub.2-12 alkylidene; R.sub.15 is hydrogen, metal cation, acetylamido, alkoxyacetoyl or a related moiety which delivers the carboxylate in vivo; the dotted line is an optional double bond; with the proviso that when R.sub.10 is an alkylidene moiety, the double bond is absent; and W is nitrogen or carbon bearing a hydrogen, or R.sub.4, R.sub.5 or R.sub.6 as hereinbefore defined; or pharmaceutical salts thereof, are useful in the treatment of disorders associated with smooth muscle contraction via potassium channel and chloride channel modulation.
式为##STR1##的化合物,其中:R.sub.1、R.sub.2、R.sub.3、R.sub.4、R.sub.5、R.sub.6、R.sub.7和R.sub.8分别独立地为氢、COOR.sub.15、卤素、硝基、氰基、C.sub.1-10烷氧基、C.sub.1-10卤代烷氧基、磺酸、C.sub.1-10烷基磺酰基、C.sub.6-12芳基磺酰基、C.sub.6-12芳基烷基磺酰基、C.sub.1-10烷基亚磺酰基、C.sub.6-12烷基亚磺酰基、C.sub.6-12芳基烷基亚磺酰基、磺酰胺基、C.sub.1-10烷基磺酰胺基、C.sub.6-12烷基磺酰胺基、C.sub.1-10酰基、C.sub.6-12芳基酰基、C.sub.6-12芳基烷基酰基、氨基、C.sub.1-10烷基氨基、C.sub.2-10二烷基氨基、C.sub.6-12芳基烷基氨基、C.sub.6-12芳基氨基、羧酰胺基、C.sub.1-10烷基羧酰胺基、C.sub.6-12芳基羧酰胺基、C.sub.1-10卤代烷基、C.sub.1-10烷基、C.sub.2-12烯基、C.sub.6-12芳基、C.sub.6-12芳基烷基;但至少有R.sub.4和R.sub.5中的一个为COOR.sub.15;R.sub.9为氢、C.sub.1-10烷基和C.sub.1-10卤代烷基;R.sub.10为氢、C.sub.1-10烷基、C.sub.1-10卤代烷基或C.sub.2-12烷基亚基;R.sub.15为氢、金属阳离子、乙酰胺基、烷氧乙酰基或在体内释放羧酸根的相关基团;虚线为可选的双键;但当R.sub.10为烷基亚基时,双键不存在;且W为氮或碳,带有氢、或如上所定义的R.sub.4、R.sub.5或R.sub.6;或其制药盐,在通过钾通道和氯通道调节治疗平滑肌收缩相关疾病方面有用。